Rana McKay, MD discusses emerging data in the metastatic renal cell carcinoma treatment landscape, reviewing the current standard of care and then delving into recent data updates from the CheckMate 9ER and COSMIC-313 trials.
EP. 1: Overview of Metastatic RCC and First-Line Treatment Options
Rana McKay, MD presents an overview of metastatic/stage IV RCC, touching on incidence, the typical RCC patient she sees in her practice, and available first-line treatments for metastatic clear cell RCC.
EP. 2: RCC Trial Review: Checkmate 9ER
Dr McKay reviews key trial data from the CheckMate 9ER trial including eligible patient populations, study design, and safety/efficacy data.
EP. 3: RCC Trial Review: COSMIC-313
Discussion centered around the unmet needs that the COSMIC-313 trial aims to address, as well as information about included patient populations, study design, and recent conference data.
EP. 4: Clinical Implications of Recent Developments in the RCC Treatment Landscape
Rana McKay, MD closes by offering actionable advice for community oncologists and considers the potential clinical implications of these and other emerging data.
2 Commerce Drive Cranbury, NJ 08512